Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1

Current HIV Research

Volumn 9, Issue 8, 2011, Pages 630-635

  Aghasadeghi, Mohammad Reza ^a   Salmani, Ali Sharifat ^a   Sadat, Seyed Mehdi ^a   Javadi, Foozieh ^a   Memarnejadian, Arash ^a   Vahabpour, Rouhoullah ^a   Zabihollahi, Rezvan ^a   Moshiri, Arfa ^a,b   Siadat, Seyed Davar ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cell mediated immunity; HIV 1; Neisseria meningitidis; OMV; Th 1; VLP

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MZNL4 3; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL OUTER MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG POTENCY; EX VIVO STUDY; FEMALE; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOPOTENTIATION; MEMBRANE VESICLE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE VESICLE; SPLEEN CELL; TH1 CELL; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CYTOKINES; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; TH1 CELLS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84856438921     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798998772     Document Type: Article

References (28)

1. Schooley RT, Spino C, Kuritzkes D, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 a nd 214. J Infect Dis 2000; 182(5):1357-64.
2. Wright PF, Lambert JS, Gorse GJ, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virusinfected pregnant women. J Infect Dis 1999; 180(4): 1080-88.
3. Faul EJ, Aye PP, Papaneri AB, et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009; 28(2): 299-308.
4. McKenna PM, Koser ML, Carlson KR, et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 2007; 195(7): 980-8.
5. Buffa V, Negri DR, Leone P, et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol 2006; 19(4): 690-701.
6. Weber J, Cheinsong-Popov R, Callow D, et al. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995; 13(9): 831-4.
7. Benson EM, Clarkson J, Law M, et al. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 1999; 15(2): 105-13.
8. Ye L, Wen Z, Dong K, et al. Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Response. J Biomed Biotechnol 2010: Article ID 497219, 11 pages.
9. Zabihollahi R, Sadat S, Vahabpour R, et al. Development of singlecycle replicable human immunodeficiency virus 1mutants. Acta virologica 2001; 55: 15-22.
10. Buonaguro L, Tornesello ML, Tagliamonte M, et al. Baculovirusderived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006; 80(18): 9134-43.
11. Sharifat Salmani A, Siadat SD, Norouzian D, et al. Outer membrane vesicle of Neisseria meningitidis serogroup B as an adjuvant to induce specific antibody response against the lipopolysaccharide of Brucella abortus S99. Ann Microbiol 2009; 59(1): 145-9.
12. Sadat SM, Zabihollahi R, Aghasadeghi MR, et al. Application of SCR Priming VLP Boosting as a Novel Vaccination Strategy Against HIV-1. Curr HIV Res 2011; 9: 140-7.
13. Mahdavi M, Ebtekar M, Azadmanesh K, et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in e mouse model. Acta virol 2010; 54(2): 131-6.
14. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010; 33(4): 542-54.
15. Roldao A, Candida M Mellado M, R Castilho L, et al. Virus-like particles in vaccine development. Expert Review of Vaccines 2010; 9(10): 1149-76.
16. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007; 6: 381-90.
17. Sanders H and Feavers IM. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines 2011; 10(3): 323-34.
18. Haneberg B, Dalseg R, Oftung F, et al. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant. Dev Biol Stand 1998; 92: 127-33.
19. Estevez F, Carr A, Soloranzo L, Valiente et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine1999; 18: 190-7.
20. Siadat SD, Behzadiannejad Q, Tabaraie B, et al. Evaluation of serum bactericidal activity specific for Neisseria meningitidis serogroup A and B: effect of immunization with Neisseria meningitidis serogroup A polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Res J Microbiol 2007; 2 (5): 436-44.
21. Siadat SD, Norouzian D, Tabaraie B, et al. Comparative studies of conjugated capsular polysaccharide of Neisseria meningitidis serogroup A with outer membrane vesicle of Neisseria meningitidis serogroup B Res J Microbiol 2007; 2 (4): 337-45.
22. Sardinas G, Reddin K, Pajon R, et al. Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine, 2006; 24: 206-14.
23. Tipping P G and Kitching A R. Glomerulonephritis. Th1and Th2: what's new? Clinical and Experimental Immunology 2005; 142: 207-15.
24. Hasbold J, Sui-Yin Hong J, Kehry RM, et al. Integrating Signals from IFN-g and IL-4 by B Cells: Positive and Negative Effects on CD40 Ligand-Induced Proliferation, Survival, and Division-Linked Isotype Switching to IgG1, IgE and IgG2a. J Immunol 1999; 163: 4175-81.
25. Kundu SK & Merigan TC. Heterogeneity of cytokine functions in HIV infection. Immunology 1997; 91: 234-8.
26. Clerici M & Shearer GM. A Thl-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107.
27. Arigita C, Luijkx T, Jiskoot W, et al. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives. Vaccine 2005; 23(43): 5091-8.
28. Moingeon P, Haensler J and Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001; 19: 4363-72.